US Japan Tariff Deal One Year On: Rates Came Down but Uncertainty Never Left
- The US-Japan tariff agreement marks one year on July 23 with the 15% framework intact
- NHK notes rates were cut, yet coverage of many product categories keeps shifting
- New measures kept coming: 100% generic drug tariffs announced, Section 338 used on Canada
- Japanese firms respond by relocating production to the US or absorbing the cost
- The 15% line guarantees today's rate, not tomorrow's product list
The US-Japan tariff agreement turns one year old on July 23. It capped reciprocal tariffs at 15%, brought auto duties down from threatened highs, and extracted a massive Japanese investment pledge in return. NHK's anniversary verdict is restrained: rates did fall, but opacity remains untouched—because Washington's tariff machine never stopped, it only changed targets.
This year alone brought partial relief on Section 232 aluminum, a preannounced 100% tariff on generic drugs from 2028, and the first-ever use of Section 338 against Canada at 50%. For Japanese business, the lesson is that the 15% baseline protects today's rate, not tomorrow's product list. Strategic categories—pharmaceuticals, semiconductors, critical minerals—can be singled out at any time.
The 1980s trade wars taught that friction migrates across industries rather than ending with any single accord. Today's version is more fragmented: 232, 301, 338 and emergency powers rotate in turn, each with different legal remedies.
Firms are voting with capital—TSMC's $265 billion US expansion is the extreme case, and Japanese automakers are following. Watch the generic drug rule details, the execution of Japan's investment pledge, and whether autos return to the table before the US midterms. The anniversary is halftime, not a conclusion.